Bionet Therapeutics (ROCO:7808) Change In Inventory: NT$-9.1 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7808 Bionet Therapeutics Corp ROCO:7808
20 GF Score
Price NT$33.80
! 2 Warning Signs
View Full Analysis

What is Bionet Therapeutics Change In Inventory?

Bionet Therapeutics ROCO:7808 +2.42% 20 Change In Inventory is NT$-9.1 Mil as of Jun. 2026. GuruFocus rates ROCO:7808 with a GF Score™ of 20/100. The stock has 2 warning signs investors should review.

Bionet Therapeutics's change in inventory for the quarter that ended in Jun. 2026 was NT$-11.3 Mil. It means Bionet Therapeutics's inventory increased by NT$11.3 Mil from Dec. 2025 to Jun. 2026 .

Bionet Therapeutics's change in inventory for the fiscal year that ended in Dec. 2025 was NT$-0.6 Mil. It means Bionet Therapeutics's inventory increased by NT$0.6 Mil from Dec. 2024 to Dec. 2025 .

Bionet Therapeutics's Total Inventories for the quarter that ended in Jun. 2026 was NT$41.3 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Bionet Therapeutics's Days Inventory for the quarter that ended in Jun. 2026 was 138.00.

Inventory Turnover measures how fast the company turns over its inventory within a year. Bionet Therapeutics's Inventory Turnover for the quarter that ended in Jun. 2026 was 1.32.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Bionet Therapeutics's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 0.34.

Bionet Therapeutics  (ROCO:7808) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Bionet Therapeutics's Days Inventory for the quarter that ended in is calculated as:

Days Inventory=Average Total Inventories/Cost of Goods Sold*Days in Period
=35.709/47.225*365 / 2
=138.00

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Bionet Therapeutics's Inventory Turnover for the quarter that ended in Jun. 2026 is calculated as

Inventory Turnover=Cost of Goods Sold / Average Total Inventories
=47.225 / 35.709
=1.32

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Bionet Therapeutics's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories / Revenue
=35.709 / 104.465
=0.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bionet Therapeutics Change In Inventory Related Terms

Bionet Therapeutics Change In Inventory Historical Data

* Premium members only.

The historical data trend for Bionet Therapeutics's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bionet Therapeutics Change In Inventory Chart

Bionet Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Change In Inventory
0.00 -0.37 -29.15 -0.56

Bionet Therapeutics Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Change In Inventory Get a 7-Day Free Trial -11.87 -17.28 -2.71 2.16 -11.27
ROCO:7808
20GF Score
Bionet Therapeutics Corp ROCO:7808
Change In Inventory is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bionet Therapeutics Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-9.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Inventory →
What does a Change In Inventory of NT$-9.1 Mil mean?
Bionet Therapeutics (ROCO:7808) has a Change In Inventory of NT$-9.1 Mil as of Jun. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Bionet Therapeutics and its competitors.
Is Bionet Therapeutics' Change In Inventory too high?
Bionet Therapeutics' current Change In Inventory is NT$-9.1 Mil. Overall, Bionet Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Bionet Therapeutics' Change In Inventory compare to VRTX and REGN?
Bionet Therapeutics' Change In Inventory of NT$-9.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Biotechnology company?
A good Change In Inventory depends on the Biotechnology industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Bionet Therapeutics and its competitors. Bionet Therapeutics's current Change In Inventory is NT$-9.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionet Therapeutics stock overvalued right now?
Bionet Therapeutics (ROCO:7808) has a current Change In Inventory of NT$-9.1 Mil. The current Change In Inventory is NT$-9.1 Mil. Bionet Therapeutics' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Bionet Therapeutics (ROCO:7808), the current Change In Inventory is NT$-9.1 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bionet Therapeutics Business Description

Address No.28, Lane. 36 , Xinhu 1st Road, 1st Floor, Neihu District, Taipei, TWN, 11497
Bionet Therapeutics Corp is a patient-focused on regenerative medicinal products, R&D, exosomes, and gene/cell therapy biopharmaceutical company. The group develops, manufactures, and provides regenerative medicine preparations and cellular therapies to meet the evolving health needs of people at different stages of life. It focused on treatments that improve patient outcomes. It provides Cell Therapy Products and CRDMO Services.
20GF Score

Get the complete analysis for ROCO:7808

Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$33.80
Price